Summary
Boston Scientific Corporation (BSX) has filed an 8-K report detailing changes within its Board of Directors and outlining its executive compensation plans for 2024. Two long-serving directors, Nelda J. Connors and David J. Roux, have announced they will not seek re-election at the 2024 Annual Meeting of Stockholders. Their departures are amicable and not due to any disagreements with the company. The Board will consider the future composition and size of its board in light of these changes. More significantly for investors focused on executive compensation and performance alignment, the company has approved its 2024 Annual Bonus Plan and two Performance Share Programs (PSPs) for 2024. The Annual Bonus Plan links cash incentives to corporate performance metrics including global sales, adjusted earnings per share, operating income, and quality/ESG goals, with a potential maximum payout of 150% of the target bonus. The PSPs, comprising a Relative Total Shareholder Return (rTSR) program and an Organic Net Sales Growth program, are designed to align executive pay with long-term shareholder value creation over a three-year period. These programs reinforce a pay-for-performance philosophy, with potential awards ranging from 0% to 200% of target based on the achievement of specified metrics.
Key Highlights
- 1Two Board members, Nelda J. Connors and David J. Roux, will not stand for re-election at the 2024 Annual Meeting of Stockholders.
- 2Departures of Directors Connors and Roux are stated to be voluntary and without disagreement with the Company.
- 3The Board approved the 2024 Annual Bonus Plan, effective January 1, 2024.
- 4Annual bonuses will be tied to corporate performance metrics including global sales, adjusted EPS, operating income, and quality/ESG goals.
- 5Maximum payout for the 2024 Annual Bonus Plan is 150% of the aggregate target annual bonus.
- 6Two new Performance Share Programs for 2024 were approved: a Relative Total Shareholder Return (rTSR) PSP and an Organic Net Sales Growth PSP.
- 7These PSPs aim to align executive compensation with long-term stockholder interests and company performance over a three-year period, with potential awards up to 200% of target.